Biogen announces Lucentis® (ranibizumab) biosimilar Byooviz™ approved in Canada

Mar 2, 2023

Biogen Canada Inc. announced that its Lucentis® (ranibizumab) biosimilar Byooviz™ is available in Canada following approval by Health Canada for treatment of serious eye disorders including neovascular (wet) age-related macular degeneration. On 2 June 2022, Byooviz™ was launched in the US.

 
 

Print Page Mail Article